Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice by De Logu, F et al.
ARTICLE
Schwann cell TRPA1 mediates neuroinflammation
that sustains macrophage-dependent neuropathic
pain in mice
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It is known that transient receptor potential ankyrin 1 (TRPA1) channels, expressed by
nociceptors, contribute to neuropathic pain. Here we show that TRPA1 is also expressed in
Schwann cells. We found that in mice with partial sciatic nerve ligation, TRPA1 silencing in
nociceptors attenuated mechanical allodynia, without affecting macrophage infiltration and
oxidative stress, whereas TRPA1 silencing in Schwann cells reduced both allodynia and
neuroinflammation. Activation of Schwann cell TRPA1 evoked NADPH oxidase 1 (NOX1)-
dependent H2O2 release, and silencing or blocking Schwann cell NOX1 attenuated nerve
injury-induced macrophage infiltration, oxidative stress and allodynia. Furthermore, the
NOX2-dependent oxidative burst, produced by macrophages recruited to the perineural
space activated the TRPA1–NOX1 pathway in Schwann cells, but not TRPA1 in nociceptors.
Schwann cell TRPA1 generates a spatially constrained gradient of oxidative stress, which
maintains macrophage infiltration to the injured nerve, and sends paracrine signals to activate
TRPA1 of ensheathed nociceptors to sustain mechanical allodynia.
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Neuropathic pain, which is defined as pain caused by alesion or disease of the somatosensory nervous system1,encompasses a large variety of conditions2. Lesions of the
peripheral nervous system can cause lifelong neuropathic pain.
Following peripheral nerve injury, local infiltration of inflam-
matory cells, a hallmark of Wallerian degeneration, occurs3–5,
and is associated with the development of neuropathic pain.
Although the infiltration of macrophages into the damaged nerve
trunk is known to induce mechanical allodynia in mice with
sciatic nerve injury6–9, the precise pathway by which inflamma-
tory cells cause persistent allodynia is only partially defined. A
series of mediators have been reported to contribute to macro-
phage infiltration in the damaged nerve10. Notably, inhibition of
the chemokine (C–C motif) ligand 2 (CCL2) has been shown to
attenuate neuroinflammation and allodynia7,8,11. Oxidative stress
contributes to neuropathic pain, since antioxidants attenuate
mechanical hypersensitivity in mouse models, including chronic
constriction of the sciatic nerve12 and spinal nerve ligation13.
The transient receptor potential ankyrin 1 (TRPA1) channel is
highly expressed by a subpopulation of primary sensory neu-
rons14,15 that contain and release the proinflammatory neuro-
peptides substance P (SP) and calcitonin gene-related peptide
(CGRP)15. TRPA1 is activated by a series of exogenous agents,
including allyl isothiocyanate (AITC)16,17, and is typically sensi-
tive to the redox state of the milieu18. Notably, a series of reactive
oxygen, nitrogen or carbonyl species, including hydrogen per-
oxide (H2O2), activate TRPA1, resulting in nociceptor stimulation
or sensitization19–24. TRPA1 has been shown to mediate
mechanical hypersensitivity in different models of inflammatory
and neuropathic pain, including those evoked by peripheral nerve
injury25–29.
Recent findings in mice with trigeminal nerve injury (con-
striction of the infraorbital nerve, CION) show that macrophages,
recruited by a CCL2-dependent process, increase H2O2 levels
within the site of nerve injury30. The resulting oxidative stress and
the ensuing increases in reactive carbonyl species were proposed
to mediate prolonged mechanical allodynia by gating TRPA1 in
trigeminal nerve fibers30. Thus, TRPA1, expressed by primary
sensory neurons, appears to be the target of the macrophage-
dependent oxidative burst required to promote neuropathic pain.
Here, we surprisingly found that pharmacological blockade or
genetic deletion of TRPA1 not only induced the expected inhi-
bition of mechanical allodynia, but also suppressed macrophage
infiltration and H2O2 generation in the injured nerve. The current
study was undertaken to identify the cellular and molecular
mechanisms responsible for this TRPA1-mediated macrophage
infiltration and generation of oxidative stress.
By using pharmacological and genetic approaches to disrupt
TRPA1, including conditional deletion in Schwann cells, we
found that Schwann cells that ensheath the injured sciatic nerve
axons express TRPA1. Macrophages, which are recruited by
CCL2, generate a NADPH oxidase-2 (NOX2)-dependent oxida-
tive burst that targets Schwann cell TRPA1. TRPA1, via NOX1,
produces sustained oxidative stress that maintains, in a spatially
confined manner, macrophage infiltration into the injured nerve,
and which activates TRPA1 on nociceptor nerve fibers to produce
allodynia.
Results
TRPA1 mediates neuroinflammation. In C57BL/6 mice pSNL,
but not sham surgery (Fig. 1a), induced prolonged (3–20 days)
mechanical allodynia (Fig. 1b) accompanied by macrophage (F4/
80+ cells) recruitment (Fig. 1c, e and Supplementary Fig. 1) and
oxidative stress (H2O2) generation (Fig. 1d) within the injured
nerve. Trpa1 (Fig. 1f), but not Trpv1 or Trpv4 (Supplementary
Fig. 2a), deletion prevented mechanical allodynia. Trpa1, but not
Trpv1 or Trpv4, deletion also attenuated cold allodynia, but this
response was not further investigated in the present study (Sup-
plementary Fig. 2b). Heat hyperalgesia was unaffected by Trpa1,
Trpv1, and Trpv4 deletion (Supplementary Fig. 2c). As previously
reported28,30,31 in similar models, at day 10 after pSNL (all
measurements were at 10 days unless otherwise specified),
TRPA1 antagonists (HC-030031, A-967079) and antioxidants (α-
lipoic acid (αLA) and phenyl-N-tert-butylnitrone (PBN)) (Fig. 1g
and Supplementary Fig. 3a) reversed mechanical allodynia.
Treatments for 3 days with the monocyte-depleting agent clo-
dronate32 or an anti-CCL2 antibody (CCL2-Ab)30,33 attenuated
allodynia, macrophage infiltration and H2O2 generation (Sup-
plementary Fig. 4a–c), confirming the proalgesic role of these
cells.
Other inflammatory cells, which are recruited to sites of nerve
injury, may also contribute to mechanical allodynia9,34. To
explore their role in the delayed phase of mechanical allodynia,
the number of neutrophils and T lymphocytes was evaluated in
the nerve trunk at day 10 after surgery. Although both
neutrophils (Ly6g+ cells) and T lymphocytes (CD8+ cells) were
increased by pSNL (Supplementary Fig. 4d), treatment with
clodronate, which markedly attenuated both the infiltrating
macrophages and allodynia, did not affect the number of
neutrophils or T lymphocytes (Supplementary Fig. 4d). In
agreement with a previous report34, these data exclude the
contribution of neutrophils and T cells to mechanical allodynia
assessed 10 days after pSNL.
The hypothesis that oxidative stress produced by infiltrating
macrophages targets neuronal TRPA1 to signal neuropathic
pain30 implies that the channel inhibition reduces allodynia but
does not affect neuroinflammation. Surprisingly, Trpa1 deletion
prevented infiltration of F4/80+ cells and H2O2 generation in the
injured sciatic nerve (Fig. 1h, i). TRPA1 antagonists (Fig. 1h, j, k)
and antioxidants (Fig. 1h, l and Supplementary Fig. 3b) also
transiently reversed macrophage infiltration and H2O2 produc-
tion. Thus, the TRPA1-oxidative stress pathway mediates both
neuropathic pain and neuroinflammation in the injured nerve.
CCL2 induces neuroinflammation via TRPA1. One possible
explanation may be that TRPA1 mediates the release of the
monocyte chemoattractant, CCL2, generated by injured nerves8.
However, as neither TRPA1 deletion or antagonism nor anti-
oxidants affected CCL2 increases in ligated sciatic nerves
(Fig. 2a), the chemokine should originate from a TRPA1-
oxidative stress-independent pathway. As previously shown8,35,
local perineural CCL2 administration induced mechanical allo-
dynia, as well as producing F4/80+ cell infiltration and H2O2
generation (Fig. 2b, c). TRPA1 deletion or antagonism and
antioxidants prevented or reversed the effects of CCL2
(Fig. 2b, c). Pretreatment with clodronate, which depletes circu-
lating monocytes and thereby inhibits their neural accumula-
tion30, prevented mechanical allodynia evoked by CCL2
(Supplementary Fig. 4e). Furthermore, in mice with pSNL clo-
dronate treatment depleted macrophages and attenuated
mechanical allodynia (Supplementary Fig. 4a), but did not affect
the increased CCL2 levels within the ligated nerve trunk (Sup-
plementary Fig. 4f). Together, the present findings support the
view that oxidative stress and TRPA1 induce neuroinflammation
downstream from CCL2. There was a distinct temporal difference
between the effects of CCL2-Ab and TRPA1 antagonists/anti-
oxidants on pSNL-induced neuroinflammation and allodynia.
One-hour after HC-030031, A-967079, αLA or PBN, pSNL-
induced F4/80+ cell infiltration, H2O2 formation and allodynia
were all prominently inhibited (Fig. 1g, h, j–l and Supplementary
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Fig. 3b), whereas a high dose of the CCL2-Ab, which at 1 h
already attenuated neural CCL2 levels, was completely ineffective
(over 6 h) in reducing mechanical allodynia (Fig. 2d). Successful
inhibition of pain and inflammation required the administration
of a lower CCL2-Ab dose for 3 consecutive days that, as
expected30,33, also reduced CCL2 levels in the nerve trunk
(Supplementary Fig. 4b). Thus, while TRPA1-antagonism/anti-
oxidants rapidly (within 1 h) reversed neuroinflammation, CCL2-
blockade required a much longer time (3 days) to produce the
same inhibitory effects30,33.
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Schwann cells express TRPA1 and release H2O2. Nerve fibers,
macrophages and Schwann cells within the injured nerve trunk
could potentially mediate TRPA1-dependent oxidative stress. By
targeting TRPV1, resiniferatoxin (RTX) defunctionalizes TRPV1
+/TRPA1+ neurons36–38. RTX abolished nociceptive responses to
TRPV1 (capsaicin) and AITC (Supplementary Fig. 5a) and
reversed pSNL-evoked allodynia, but did not affect F4/80+ cell
infiltration and H2O2 generation (Supplementary Fig. 5b). Thus,
TRPV1+/TRPA1+ nerve fibers mediate neuropathic pain but not
neuroinflammation. Naïve or lipopolysaccharide-activated mouse
peritoneal macrophages in culture neither expressed TRPA1
mRNA (RT-qPCR), TRPA1 protein (immunocytochemistry) nor
responded to AITC (Ca2+-signaling) (Supplementary Fig. 5c–e).
Thus, macrophages infiltrating the injured nerve cannot generate
TRPA1-dependent oxidative stress.
Schwann cells ensheath nerve fibers, including C-fiber
nociceptors, and represent 90% of the nucleated cells of the
nerve trunk39. We localized immunoreactive TRPA1 to PGP9.5+
nerve fibers and to S-100+ or SOX10+ Schwann cells in the sciatic
nerve trunk from C57BL/6 mice (Fig. 3a–c). TRPA1 immunor-
eactivity was not detected in dorsal root ganglia (DRG, L4-L6)
(Fig. 3d) or in S-100+ cells in the sciatic nerve trunk (Fig. 3e) from
Trpa1−/− mice, which confirms antibody selectivity. Expression
of TRPA1 (protein and mRNA) in cultured mouse Schwann cells
was confirmed by immunofluorescence, western blotting and RT-
qPCR (Fig. 3f–h and Supplementary Fig. 6a). Furthermore,
AITC-induced intracellular Ca2+ response in cultured Schwann
cells from wild type mice, which was attenuated by HC-030031
(Fig. 4a). In contrast, capsaicin or a TRPV4 agonist
(GSK1016790A) failed to produce any Ca2+ response (Fig. 4a).
Importantly, Schwann cells from Trpa1+/+ mice, but not from
Trpa1−/− mice, responded to AITC (Fig. 4b). The ability of
TRPA1 to promote oxidative stress was explored by measuring
H2O2 generation. Both AITC and H2O2, which has been shown to
gate TRPA120, stimulated H2O2 release from HEK293 cells
expressing the human TRPA1 (hTRPA1-HEK293 cells), but not
from untransfected HEK293 cells (Fig. 4c, d). AITC or H2O2 also
produced a time- and Ca2+-dependent H2O2 generation in
Schwann cells, which was prevented by HC-030031 (Fig. 4e).
Thus, Schwann cells generate H2O2 in response to TRPA1
activation.
Schwann cells generate oxidative stress via TRPA1 and NOX1.
Different NOXs play a key role in oxidative stress40. While we
observed that macrophages contain exclusively NOX2 (mRNA
and protein) (Supplementary Fig. 5c, f, g), cultured Schwann cells
expressed NOX1, NOX2 and NOX4 mRNAs (Supplementary
Fig. 6a). Yet, only NOX1 protein was detected by immuno-
fluorescence (Fig. 5a and Supplementary Fig. 6b). Functional data
corroborated the molecular/morphological findings as the selec-
tive NOX2-inhibitor (Gp91ds-tat peptide)41, but not the NOX1/
NOX4 inhibitor (GKT13783)42, attenuated phorbol myristate
acetate-stimulated H2O2 release from cultured peritoneal mac-
rophages (Supplementary Fig. 5h). However, GKT13783, but not
gp91ds-tat peptide, inhibited AITC-induced H2O2 release from
cultured Schwann cells (Supplementary Fig. 5i), indicating a
major role for NOX1. 1 h after the administration of 2-
acetylphenothiazine (ML171, selective NOX1-inhibitor)43 or
GKT13783, pSNL-induced allodynia and neuroinflammation
were attenuated (Fig. 5b and Supplementary Fig. 6c), whereas
gp91ds-tat peptide was ineffective (Supplementary Fig. 6d).
Perineural administration of antisense oligonucleotides (AS-
ODN) for NOX1, NOX2 or NOX4 effectively knocked down
respective mRNA expression (Fig. 5c and Supplementary Fig. 6e,
g). However, only NOX1 AS-ODN attenuated pSNL-induced
allodynia, macrophage infiltration and H2O2 generation (Fig. 5d
and Supplementary Fig. 6f, h).
To define the contribution of the TRPA1/NOX1 pathway of
Schwann cells to neuroinflammation and neuropathic pain
evoked by pSNL, antisense TRPA1 oligonucleotide (TRPA1 AS-
ODN) or their mismatched (TRPA1 MM-ODN) analogs were
administered to pSNL mice by perineural or intrathecal route
(Fig. 6a, f). Perineural treatment with TRPA1 AS-ODN did not
affect expression of TRPA1 mRNA and immunoreactivity in
DRGs (L4-L6), or acute nociceptive responses to perineural AITC
or capsaicin (Fig. 6b). However, it markedly reduced TRPA1
mRNA and the TRPA1/S-100 overlap (Fig. 6c) in injured sciatic
nerves, and inhibited pSNL-evoked allodynia, neural F4/80+ cell
infiltration, and H2O2 generation (Fig. 6d, e). Thus, Schwann cell
TRPA1 silencing preserved TRPA1-mediated acute nociceptive
signaling, but disrupted pSNL-evoked neuroinflammation and
allodynia. Intrathecal administration of TRPA1 AS-ODN (Fig. 6f)
down-regulated TRPA1 mRNA and immunoreactivity44 in DRGs
(L4-L6), suppressed the acute nociception by perineural AITC,
but not capsaicin, and inhibited pSNL-evoked allodynia (Fig. 6g, i).
However, TRPA1 mRNA, the TRPA1/S-100 overlap, and pSNL-
evoked F4/80+ cell infiltration and H2O2 generation in injured
nerves were unaffected (Fig. 6h, j).
HC-030031 reduced the number of fluorescent macrophages
accumulated at the site of pSNL by ~50% (Fig. 7a), assessed by
in vivo imaging45. Increased F4/80+ cells were found in the tissue
surrounding the injured nerve trunk (Fig. 7b). HC-030031 or αLA
reduced F4/80+ cells in the pSNL-injured nerve trunk and
neighboring tissue, but not in perineural tissue distant from the
injury site (Fig. 7b). The Schwann cell-mediated TRPA1/NOX1
pathway regulates the final stages of macrophage migration from
the circulation into the injured nerve trunk, in a manner
dependent on the H2O2 concentration gradient.
To provide further support for the involvement of Schwann
cell TRPA1 in orchestrating neuroinflammation and ensuing
neuropathic pain in the pSNL model, we selectively deleted
TRPA1 from Schwann cells. We crossed a floxed TRPA1 mouse
Fig. 1 TRPA1 mediates pSNL-evoked allodynia and neuroinflammation. a Drawing representing the pSNL surgery in mice. b–e Time-dependent (3–20 days,
d) mechanical allodynia (b), number and representative images of macrophages (F4/80+ cells) (c, e) and H2O2 content (d) in the sciatic nerve trunk
induced by pSNL in C57BL/6 compared to sham mice (n= 6, *P< 0.005, **P< 0.01 ***P< 0.001 pSNL vs. Sham; two-way ANOVA followed by Bonferroni
post hoc analyses and unpaired two-tailed Student’s t-test). f Time-dependent (3–20 d) mechanical allodynia in sham/pSNL Trpa1+/+/Trpa1−/− mice (n=
8, ***P< 0.001 pSNL+/+ vs. Sham+/+; n= 6, §P< 0.05 and §§§P< 0.001 pSNL−/− vs. pSNL+/+; two-way ANOVA followed by Bonferroni post hoc
analyses). gMechanical allodynia (at day 10 after surgery) in sham/pSNL mice after HC-030031 (HC03, 100mg kg−1, i.p.), A-967079 (A96, 100mg/kg, i.
p.) and α-lipoic acid (αLA, 100mg kg−1, i.p.) or respective vehicles (veh, 4% DMSO and 4% tween 80 in isotonic saline) (n= 6, ***P< 0.001 pSNL veh vs.
Sham veh; §§§P< 0.001 pSNL-HC03, A96 or αLA vs. pSNL-veh; two-way ANOVA followed by Bonferroni post hoc analyses). h–l Representative images,
number of F4/80+ cells, and H2O2 content in the sciatic nerve of sham/pSNL Trpa1+/+/Trpa1−/− and C57BL/6 mice, before (BL) and 1–6 h after HC03,
A96, αLA (all, 100mg kg−1, i.p.) or respective vehicles (veh, 4% DMSO and 4% tween 80 in isotonic saline) (n= 6, **P< 0.01 and ***P< 0.001 pSNL Trpa1
+/+ vs. Sham-Trpa1+/+ and pSNL veh vs. Sham veh; §§P< 0.01 and §§§P< 0.001 pSNL Trpa1−/− vs. pSNL-Trpa1+/+ and pSNL HC03, A96 or αLA vs. pSNL-
veh; two-way and one-way ANOVA followed by Bonferroni post hoc analyses). (Scale bars: 50 μm; (e, h) dashed lines, perineurium). Data are represented
as mean± s.e.m
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(TRPA1fl/fl) with a Plp1-Cre/ERT mouse in which Cre recombi-
nase is expressed in Schwann cells/oligodendrocytes (Plp1-
CreERT;Trpa1fl/fl mice). Plp1-CreERT;Trpa1fl/fl mice were treated
with tamoxifen to induce TRPA1 deletion in Schwann cells. In
Plp1-CreERT;Trpa1fl/fl mice, the ability of intraplantar injection of
AITC to evoke acute nociception was unaffected (Fig. 8a). In
nerve trunks from Plp1-CreERT;Trpa1fl/fl mice, immunoreactive
TRPA1 was detected in PGP9.5+ nerve fibers, indicating
preservation of TRPA1 expression in sensory nerve fibers
(Fig. 8b). In contrast, immunoreactive TRPA1 was markedly
down-regulated in S100+ cells, but not in PGP9.5+ nerve fibers,
confirming effective channel deletion in Schwann cells (Fig. 8b).
Functional confirmation of the selective conditional Trpa1 gene
knock-out was obtained by the failure of AITC to increase [Ca2+]i
in Schwann cells from Plp1-CreERT;Trpa1fl/fl mice (Fig. 8c). In
Plp1-CreERT;Trpa1fl/fl mice, mechanical allodynia (Fig. 8d) and
macrophage recruitment and oxidative stress (H2O2 generation)
in the injured nerve (Fig. 8e) were markedly attenuated. Thus,
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tissue-selective deletion shows that Schwann cell TRPA1
promotes macrophage infiltration and oxidative stress in injured
nerve trunks, whereas nociceptor TRPA1 does not contribute to
neuroinflammation.
Discussion
We report the discovery of a role for TRPA1 in Schwann cells in
neuroinflammation and ensuing neuropathic pain. Previous stu-
dies have implicated TRPA1 in primary sensory neurons as a
mediator of mechanical allodynia14,15,46. The established capacity
of TRPA1 to sense oxidative stress15,18,19,22, and recent data
obtained in a model of neuropathic pain caused by trigeminal
nerve injury30, led to the hypothesis that mechanical allodynia is
sustained by the oxidative burden generated by infiltrating mac-
rophages that continuously target TRPA1 in nerve fibers. Our
present results support the view that nociceptor TRPA1 is the
ultimate peripheral target to signal pSNL-evoked allodynia to the
brain. However, our findings demonstrate that Schwann cell
TRPA1, rather than neuronal TRPA1, orchestrates the neuroin-
flammation and oxidative stress that sustain neuropathic pain
(Fig. 9).
Diverse lines of evidence support the hypothesis that Schwann
cell TRPA1 is necessary and sufficient to mediate neuroin-
flammation and neuropathic pain. TRPA1 blockade, achieved
with chemically unrelated antagonists, markedly decreased mac-
rophage accumulation and the oxidative burden in the injured
nerve. Studies of Trpa1−/− mice confirmed the findings obtained
with pharmacological antagonists. Although in the present model
of neuropathic pain both approaches unequivocally demonstrated
the key role of TRPA1, they could not discriminate between the
specific contribution of neuronal vs. non-neuronal channels.
TRPA1 is expressed by peptidergic primary sensory neurons that,
by releasing SP and CGRP, promote neurogenic
inflammation47–49. Stimulants of neurogenic inflammation,
including the prototypic TRPV1 agonist capsaicin, evoke a
transient and moderate inflammatory response, which is che-
mokine/cytokine-independent and is characterized by CGRP-
mediated arteriole vasodilatation and SP-mediated plasma pro-
tein and leukocyte extravasation from postcapillary venules15,50.
Although neurogenic inflammation neither induces the infiltra-
tion of inflammatory cells after nerve injury nor mediate neu-
ropathic pain, it does contribute to migraine attacks51,52. In
contrast, neuroinflammation is a localized and persistent
inflammatory process that is confined to the injured nerve and
neighboring tissues. The hallmarks of neuroinflammation
encompasses chronic infiltration of leukocytes, activation of glial
cells, and increased production of inflammatory mediators,
including a series of cytokines and chemokines and neuropathic
pain5,53. Experiments with RTX, which defunctionalizes TRPV1/
TRPA1-expressing neurons and abrogate their sensory and
proinflammatory efferent functions36,54,55, exclude the possibility
that TRPA1-dependent neurogenic inflammation contributes to
pSNL-evoked neuroinflammation. RTX attenuated mechanical
allodynia, but not macrophage number or H2O2 levels, which
suggests that TRPA1 present in TRPV1+ peptidergic neurons may
signal allodynia, but does not promote the neuroinflammatory
component.
We observed that the site-specific (perineural vs. intrathecal)
administration of TRPA1 AS-ODN efficiently disrupted TRPA1
expressed in nociceptors or Schwann cells, respectively, as
demonstrated by behavioral and molecular studies. A reduced
expression of the nociceptor TRPA1 was associated with
attenuation of pain, whereas diminished expression of Schwann
cell TRPA1 inhibited both pain and neuroinflammation. These
findings support the hypothesis that non-neuronal TRPA1
channels exert a key role in inflammatory cell recruitment and
oxidative stress generation. Confirmation of this proposal was
derived from experiments with Plp1-CreERT;Trpa1fl/fl mice, which
exhibited selective depletion of Trpa1 in Schwann cells and
markedly attenuated neuroinflammation and mechanical allody-
nia. This localization of TRPA1 in Schwann cells represents a
plausible explanation for the widely-reported efficacy of TRPA1
antagonists in different models of neuropathic pain produced by
nerve injury25,27,28,30, where neuroinflammation is the underlying
mechanism of the ongoing pain condition.
The CCL2 receptor (CCR2) is expressed by primary sensory
neurons56,57, and CCL2 has been shown to increase TRPV1
expression58 and to sensitize TRPA1 and TRPV159 in nocicep-
tors. CCL2 is upregulated during neuronal injury, and may
activate its cognate receptor CCR2 on TRPV1-positive nocicep-
tors58. The CCL2 system has been reported to augment noci-
ceptor sensitivity by increasing TRPV1 expression58 and TRPA1
and TRPV1 function59. The present findings, showing that CCL2
rapidly increases neuronal hypersensitivity, support the view that
this chemokine may directly stimulate primary sensory neurons,
thereby enhancing mechanical allodynia under short-lived
experimental conditions59,60. However, as indicated by studies
with macrophage depletion, CCL2 requires the contribution of
infiltrated macrophages within the injured nerve trunk to sustain
the allodynia in a prolonged model of neuropathic pain, such as
the pSNL in mice. Neutrophils and lymphocytes have been
reported to accumulate, although at a minor extent compared to
macrophages, at sites of nerve damage, where they may con-
tribute to the initial9, but not delayed phase34, of neuropathic
pain. Their role in mechanical allodynia at day 10 after surgery is
further excluded by the present observation that clodronate
attenuated allodynia and macrophage infiltration, whereas the
influx of neutrophils and lymphocytes was unchanged.
Our results reveal distinct kinetics of macrophage accumula-
tion by CCL2 and the TRPA1/oxidative stress pathways. Despite
Fig. 2 TRPA1 mediates CCL2-evoked allodynia and neuroinflammation. a CCL2 levels in sciatic nerves (at day 10 after surgery) of sham/pSNL Trpa1
+/+/Trpa1−/− and C57BL/6 mice after HC-030031 (HC03, 100mg kg−1, i.p.), α-lipoic acid (αLA, 100mg kg−1, i.p.) or respective vehicles (veh, 4% DMSO
and 4% tween 80 in isotonic saline) (n= 6, ***P< 0.001 pSNL-Trpa1+/+ vs. sham-Trpa1+/+ and pSNL-veh vs. sham-veh; one-way ANOVA followed by
Bonferroni post hoc analyses). b Mechanical allodynia induced by perineural CCL2 (0.1–1 µg) or vehicle (veh, isotonic saline) in C57BL/6 mice (n= 4, ***P
< 0.001 veh vs. CCL2 (1 µg), two-way ANOVA followed by Bonferroni post hoc analyses) and CCL2 (1 µg) in Trpa1+/+/Trpa1−/− and after HC03, αLA (both,
100mg/kg, i.p.) or respective vehicles (veh, 4% DMSO and 4% tween 80 in isotonic saline) in C57BL/6 mice (n= 4, ***P< 0.001 Trpa1+/+ CCL2 vs. Trpa1
+/+veh; CCL2 veh HC03, αLA vs. veh CCL2; §§§P< 0.001 Trpa1−/− CCL2 vs. Trpa1+/+ CCL2 and CCL2 HC03, αLA vs. CCL2 veh HC03, αLA; two-way
ANOVA followed by Bonferroni post hoc analyses). c Representative images, F4/80+ cell number and H2O2 content in sciatic nerves of mice treated with
perineural CCL2 (1 µg) after HC03, αLA (both, 100mg kg−1, i.p.) or respective vehicles (veh, 4% DMSO and 4% tween 80 in isotonic saline) (n= 5, ***P<
0.001 CCL2 vs. veh HC03, αLA; §§§P< 0.001 CCL2 HC03, αLA vs. CCL2 veh HC03, αLA; one-way ANOVA followed by Bonferroni post hoc analyses)
(Scale bars: 50 μm, dashed lines indicate perineurium). d CCL2 levels, mechanical allodynia, F4/80+ cell number and H2O2 content in sciatic nerves (at day
10 after surgery) of sham/pSNL C57BL/6 mice after an anti-CCL2 antibody (CCL2-Ab) or IgG2B control (120 µg 200 µl−1, i.p., single administration) (n= 6,
***P< 0.001 pSNL-CCL2-Ab vs. sham-CCL2-Ab; §§§P< 0.001 pSNL-CCL2-Ab vs. pSNL-IgG2B; one-way ANOVA followed by Bonferroni post hoc
analyses). Data are represented as mean± s.e.m
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its ability to suppress perineural CCL2 levels within 1 h, a high
dose of the CCL2-Ab failed to affect macrophage number, oxi-
dative stress, and allodynia over 6 h. In contrast, a prolonged, 3-
day antibody treatment was required for successful inhibition of
neuroinflammation and pain30. The persistent temporal frame
necessary for CCL2 inhibition to attenuate neuroinflammation
and pain is, therefore, markedly different from the very short
time-period (1–3 h) required by TRPA1 antagonists or anti-
oxidants to produce the same inhibitory responses. Oxidative
burst has been reported to exert a chemoattractant activity toward
macrophages61, which is limited by time and spatial constrains.
Leukocyte-induced H2O2 release is a rapid event, lasting a few
seconds62, and is spatially confined to a range that does not
exceed a few hundred µm63 (Fig. 7b). Our data, including those
obtained by genetic or pharmacological manipulation of NOXs,
are consistent with previous observations. Macrophages express
solely NOX240, while Schwann cells, which potentially express
mRNAs for NOX1, NOX2, and NOX4, apparently express only
the NOX1 protein. Since NOX1, but not NOX2 or NOX4, inhi-
bitors or AS-ODNs attenuated neuroinflammation and allodynia,
it is possible to propose that Schwann cell TRPA1 activates
intracellular pathways, including Ca2+ transients, resulting in
NOX1-dependent release of oxidant molecules. Furthermore, the
prominent role of NOX1, but not of NOX2, in generating allo-
dynia excludes phagocyte-derived oxidative burst in the final
activation of nociceptor TRPA1.
The most parsimonious explanation of the present results is
that oxidative stress generated by Schwann cell TRPA1/NOX1
has bidirectional effects. The inwardly released H2O2 targets
TRPA1 on adjacent nociceptor nerve fibers in a paracrine fashion
to sustain allodynia. The outwardly released H2O2 promotes the
final part (about 200 µm) of the journey of macrophages, which,
deriving from the blood stream, slowly accumulate into the
perineural space following the CCL2 gradient. Thereafter, fol-
lowing the Schwann cell-derived oxidative stress gradient, mac-
rophages rapidly pass across the perineurium to enter the
damaged nerve trunk (Fig. 9). TRPA1 has been identified in
oligodendrocytes, with possible detrimental roles in ischemia and
neurodegeneration64. Herein, we extend this observation to
Schwann cells, the peripheral analogs of oligodendrocytes, which,
via TRPA1, orchestrate neuroinflammation and ensuing neuro-
pathic pain. Amelioration of neuropathic pain by currently
developed TRPA1 antagonists may derive from their ability to
attenuate macrophage-dependent neuroinflammation.
Methods
Animals and drugs. In vivo experiments and tissue collection were carried out
according to the European Union (EU) guidelines for animal care procedures and
the Italian legislation (DLgs 26/2014) application of the EU Directive 2010/63/EU.
Studies were conducted under University of Florence research permits #204/2012-
B and #194/2015-PR. C57BL/6 mice (male, 20–25 g, 5–6 weeks; Envigo, Milan,
Italy), littermate wild type (Trpa1+/+) and TRPA1-deficient (Trpa1−/−) mice
(25–30 g, 5–8 weeks), generated by heterozygotes on a C57BL/6 background
b
e
d
c
Trpa1–/–
S100-TRPA1
Trpa1+/+ 
S100-TRPA1
MergeTRPA1SOX10
f
g
R
el
at
iv
e 
R
N
A 
ex
pr
es
sio
n
1.0
0.000
0.002
0.004
SO
X1
0
S1
00
TR
PA
1
0.5
h
a S100 TRPA1 Merge
Trpa1–/–
Trpa1+/+
SOX10 TRPA1 Merge
TRPA1PGP 9.5 Merge
R
el
at
iv
e 
pe
rc
en
ta
ge
(on
 TR
PA
1/β
-
a
ct
in
)
0
40
80
120
Schwann cells
DRGs neurons
Schwann
cells
DRGs
neurons
TRPA1
β-actin
100
70
50
40
S100 PGP 9.5 TRPA1 Merge
Fig. 3 Schwann cells express TRPA1. a Double immunofluorescence staining of TRPA1 and S-100 and SOX10 (two specific markers for detecting Schwann
cells), in sciatic nerve from C57BL/6 mice (Scale bars: 50 μm and inset 20 μm). b 3D confocal images of TRPA1 and PGP9.5 staining in Schwann cells from
sciatic nerve trunks of C57BL/6 mice (Scale bars: 20 μm). c Triple immunofluorescence staining of S-100, PGP9.5 and TRPA1 in sciatic nerve trunks from
C57BL/6 mice (Scale bars: 20 μm and inset 10 μm). d TRPA1 staining in DRGs neurons from Trpa1+/+ and Trpa1−/−mice (Scale bars: 50 μm). e 3D confocal
image reconstructions of TRPA1 and S100 in Schwann cells from sciatic nerve trunks of Trpa1+/+ and Trpa1−/− mice. f TRPA1 and SOX-10 immunoreactivity
in cultured C57BL/6 mouse Schwann cells (Scale bars: 50 μm and inset 10 µm). g Representative blot and TRPA1 protein content in cultured Schwann cells
and DRGs neurons taken from C57BL/6 mice. Equally loaded protein was checked by expression of β-actin (n= 4 independent experiments). h TRPA1
mRNA relative expression in cultured C57BL/6 mouse Schwann cells (n= 3 replicates from two independent experiments). Data are represented as mean
± s.e.m
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01739-2 ARTICLE
NATURE COMMUNICATIONS |8:  1887 |DOI: 10.1038/s41467-017-01739-2 |www.nature.com/naturecommunications 7
(B6.129P-Trpa1tm1Kykw/J; Jackson Laboratories, Bar Harbor, ME, USA)65, wild type
(Trpv4+/+) and TRPV4-deficient (Trpv4−/−) mice (25–30 g, 5–8 weeks), generated
by heterozygotes on a C57BL/6 background66 and TRPV1-deficient mice (Trpv1
−/−; B6.129 × 1-Trpv1tm1Jul/J) backcrossed with C57BL/6 mice (Trpv1+/+) for at
least 10 generations (Jackson Laboratories, Bar Harbor, ME, USA; 25–30 g,
5–8 weeks), were used. B6.Cg-Tg(Plp1-CreERT)3Pop/J mice (Plp1-CreERT, Stock
No: 005975), expressing a tamoxifen-inducible Cre in myelinating cells (Plp1,
proteolipid protein myelin 1)67, and 129S-Trpa1tm2Kykw/J mice (floxed TRPA1,
Trpa1fl/fl, Stock No: 008650), which possess loxP sites on either side of the S5/S6
transmembrane domains of the Trpa1 gene, were obtained from Jackson Labora-
tories (Bar Harbor, ME, USA). To generate mice in which the Trpa1 gene was
conditionally silenced in Schwann cells/oligodendrocytes homozygous Trpa1fl/fl
mice were crossed with hemizygous Plp1-CreERT mice.
The progeny was genotyped by standard PCR for CreERT and Trpa1 alleles
(PCR protocol ID 005975; PCR protocol ID 008650, Jackson Laboratories, Bar
Harbor, ME, USA). Both positive or negative mice to CreERT and homozygous for
floxed Trpa1 (Plp1-CreERT;Trpa1fl/fl and Plp1-CreERT−;Trpa1fl/fl, respectively) were
treated with intraperitoneal (i.p.) 4-hydroxytamoxifen (1 mg 100 µl−1 in corn oil,
once a day, for 5 consecutive days)67 resulting in Cre-mediated ablation of Trpa1 in
PLP-expressing Schwann cells/oligodendrocytes. Successful Cre-driven deletion of
TRPA1 mRNA was confirmed by RT-qPCR. Mice negative to CreERT (Plp1-
CreERT−;Trpa1fl/fl) were used as control. Mice were allocated to pSNL/sham surgery
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or underwent to functional experiments (AITC challenge) 15 days after the last
tamoxifen injection. Tissues or cells used to assess the level of TRPA1 expression
were collected also 15 days after the last tamoxifen injection.
Animals were housed in a temperature- and humidity-controlled vivarium
(12 h dark/light cycle, free access to food and water, 10 animals per cage).
Behavioral experiments were performed, after 1 h of animal acclimation, in a quiet,
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temperature-controlled room (20–22 °C) between 9 a.m. and 5 p.m. The sample
sizes chosen for animal groups were adequately powered to observe the effects
based on both our past experience in similar experimental settings and data
published by others. Some animals were excluded because of failure to reach the
training criteria or mortality. Exclusions for training were based on scores
established before starting experiments and routinely used. Animals were
randomized to vehicle(s) or treatment(s) administration. The assessors (scientists
who performed in vitro and in vivo tests), were blinded to the identity (genetic
background or allocation to treatment group) of the animals. Identity of the
animals was unmasked to assessors only after data collection. Every effort has been
made to minimize the discomfort and pain of the animals in each phase of the
study. Animals were euthanized with inhaled CO2 plus 10–50% O2. HC-030031 (2-
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(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)
acetamide) was synthesized as previously described68. If not otherwise indicated,
reagents were obtained from Sigma-Aldrich (Milan, Italy).
Partial ligation of the sciatic nerve. Partial ligation of the sciatic nerve (pSNL)
was performed in C57BL/6, in Trpa1+/+ or Trpa1−/−, in Trpv1+/+ or Trpv1−/−, in
Trpv4+/+ or Trpv4−/− and in Plp1-CreERT;Trpa1fl/fl or control mice as previously
described69. Briefly, mice were anesthetized with i.p. injection of a mixture of
ketamine (90 mg kg−1) and xylazine (3 mg kg−1), the right sciatic nerve was
exposed, and a partial ligation was made by tying one-third to one half of the dorsal
portion of the sciatic nerve. In sham-operated mice, used as controls, the right
sciatic nerve was exposed, but not ligated. Mice were monitored, adequately
rehydrated, and maintained in a controlled temperature (37 °C) until fully recov-
ered from anesthesia.
Experimental design. C57BL/6, Trpa1+/+ or Trpa1−/−, Trpv1+/+ or Trpv1−/−,
Trpv4+/+, or Trpv4−/− and Plp1-CreERT;Trpa1fl/fl or control mice were randomly
allocated to pSNL or sham surgery. Ten days after surgery, C57BL/6 mice were
randomly allocated to the treatment group with i.p. administration of
TRPA1 selective antagonists, HC-030031 (HC03) or A-967079 [(1E,3E)-1-(4-
Fluorophenyl)-2-methyl-1-penten-3-one oxime] (A96) and antioxidants, α-lipoic
acid (αLA) or phenyl-N-tert-butylnitrone (PBN) (all 100 mg kg−1), the nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase (NOX) inhibitors,
GKT137831 [2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyr-
azolo[4,3-c]pyridine-3,6(2H,5H)-dione] (GKT, 60 mg kg−1, NOX1/4 selective), 2-
acetylphenothiazine (ML171, 60 mg kg−1, NOX1 selective), gp91ds-tat peptide
(10 mg kg−1, NOX2 selective) or vehicles (all 4% dimethyl sulfoxide, DMSO, 4%
tween 80 in isotonic saline, NaCl 0.9%; PBN was dissolved in NaCl 0.9%).
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Fig. 7 TRPA1 blockade and antioxidant reduced the number of fluorescent macrophages accumulated at the site of pSNL. a In vivo imaging and quantitative
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100mg kg−1, i.p.) (n= 4, ***P< 0.001 pSNL HC03 vs. pSNL Veh HC03; two-way ANOVA followed by Bonferroni post hoc analyses). b Representative
images and F4/80+-cell number surrounding the injured nerve trunk (at day 10 after surgery) of sham/pSNL-mice at BL and 1, 3 and 6 h after HC03 or
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In different experiments, at days 6, 7, 8 and 9 after surgery, pSNL or sham
C57BL/6 mice were randomly allocated to the groups receiving perineural (p.n.)
treatment (10 nmol 10 μl−1) of TRPA1, NOX1, NOX2 and NOX4 antisense (AS),
mismatch (MM) oligonucleotide (ODN) or scrambled control. TRPA1 AS-ODN
sequence was 5′-TATCGCTCCACATTGCTAC-3′, TRPA1 MM-ODN sequence
was 5′-ATTCGCCTCACATTGTCAC-3′44, NOX1 AS-ODN sequence was 5′-TTA
ACCAGCCAGTTTCCCATTG-3′, NOX2 AS-ODN sequence was 5′-TTCACAG
CCCAGTTCCCCATG T-3′, NOX4 AS-ODN sequence was 5′-TTGGCCAGCCAG
CTCCTCCA-3′, NOX1 and NOX2 scrambled p47phox sequence control was 5′-T
GAGGCTCC GTCCGCTGGAGCG-3′, NOX4 scrambled sequence was 5′-CGTCA
CGCTCAGCTCACCGT-3′70,71. Perineural injections were performed as
previously reported11,72. Briefly, compounds were injected into the region
surrounding the sciatic nerve at high thigh level of right hind limbs without skin
incision in a volume of 10 μl using a microsyringe fitted with a 30-gauge needle.
Other mice were treated with intratechal (i.t.) treatment (5 nmol 5 μl−1) of TRPA1
AS/MM-ODN44. Phosphorothioate-modified ODNs, which is reported to be more
effective in the rate of uptake and more specific in binding the target sequence,
generally increasing ODNs potency73 were used for both perineural and intrathecal
treatments. Some mice treated with TRPA1 AS/MM-ODN (p.n. or i.t.) were tested
for the acute nociceptive response to AITC (20 nmol 10 μl−1, p.n.) or CPS (1 nmol
10 μl−1, p.n.).
pSNL/sham C57BL/6 mice were treated (i.p.) with an antibody directed to the
chemokine (C–C motif) ligand 2 (CCL2) (CCL2-Ab) (R&D system, Minneapolis,
USA) with two different protocols. In the first, the CCL2-Ab or vehicle (IgG2B
Isotype Control, R&D system, Minneapolis, USA) were given at day 7, 8 and 9 (40
µg 200 µl−1, i.p.) after surgery. In the second, one single triple-dose (120 µg 200 µl
−1, i.p.) or vehicle were given at day 10 after surgery. To transiently deplete the
monocyte/macrophage population, pSNL or sham C57BL/6 mice received
liposome-encapsulated clodronate (LCL, 5 mgml−1 i.p., ClodronateLiposomes.com
Amsterdam, The Netherlands) or vehicle (liposome-encapsulated phosphate buffer
saline) at day 7, 8 and 9 after surgery.
C57BL/6 mice received subcutaneous (s.c.) resiniferatoxin (RTX, 50 μg kg−1) or
its vehicle (10% ethanol and 10% tween 80 in isotonic saline)55. pSNL or sham
surgery was carried out five days after RTX treatment when the eye wiping test
responses to both capsaicin (CPS, 1 nmol 5 µl−1) and AITC (20 nmol 5 µl−1) were
abolished (Supplementary Fig. 4A). In different experiments, perineural (p.n.)
CCL2 was given to Trpa1+/+ or Trpa1−/ mice and C57BL/6 mice (0.1, 0.5 and 1 µg
10 µl−1), which after 2 h received i.p. HC03 or αLA (both 100 mg kg−1) or vehicles.
Some C57BL/6 mice were treated with LCL (5 mgml−1 i.p.) or vehicle for 3
consecutive days and then CCL2 (1 µg 10 µl−1, p.n.) was administered.
Assessment of pain-like behaviors. Mechanical allodynia, cold hypersensitivity
and thermal hyperalgesia were assessed before (baseline) and 3, 7, 10, 20 days after
pSNL or sham surgery in C57BL/6, Trpa1+/+, Trpa1−/−, Trpv1+/+, Trpv1−/−, Trpv4
+/+, Trpv4−/−, Plp1-CreERT;Trpa1fl/fl, and control mice. In C57BL/6 mice,
mechanical allodynia was assessed before and after the various pharmacological
interventions at different time points. To measure nociceptive responses, mice were
placed in a Plexiglas chamber immediately after p.n. injection of AITC or CPS, or
intraplantar injection of AITC (10 nmol 20 µl−1) and the total time spent licking
and lifting (nociception time, s) the injected right hind limb and paw was recorded
for 5 min. Eye wiping was assayed after ocular instillation of CPS or AITC or
vehicles (2 and 4% DMSO, respectively)47. Mechanical threshold was measured by
the up-and-down paradigm74,75. Cold hypersensitivity was assessed by measuring
the acute nociceptive response to acetone-evoked evaporative cooling24.
Thermal hyperalgesia was measured by exposing the mid plantar surface of the
hind paw to a beam of radiant heat through a transparent surface, using a plantar
analgesimeter for paw stimulation (Ugo Basile, Comerio, Italy). Paw withdrawal
latency was recorded as the time from onset of the thermal stimulus to the
withdrawal response. In each paw mean withdrawal latency of three measures was
calculated. The interval between trials on the same paw was at least 5 min. The
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cutoff latency was set at 20 s to avoid tissue damage in case of failure to remove the
paw.
CCL2 enzyme-linked immunosorbent assay. The CCL2 content in the sciatic
nerve (ipsilateral to the surgery) was measured in Trpa1+/+, Trpa1−/− and C57BL/6
mice 10 days after pSNL/sham surgery and 60 min after treatment (C57BL/6 mice)
with HC03, αLA, or their vehicles and CCL2-Ab or IgG2B control (single and triple
administration) or LCL, by using a mouse CCL2/MCP-1 quantikine ELISA Kit
(R&D system, Minneapolis, USA). Samples were homogenized at 4 °C in PBS
containing a protease inhibitor cocktail tablet (Roche Diagnostics, Mannheim,
Germany). The homogenate was then centrifuged (10,000 × g, 20 min, 4 °C);
supernatants were collected and assayed according to the manufacturer’s instruc-
tions. The concentration of CCL2 was expressed in pg/mg of total protein
content76.
Measurement of H2O2 content in tissue. The H2O2 content of the sciatic nerve
(ipsilateral to the surgery) was firstly determined in C57BL/6 mice at day 3, 7, 10
and 20 after pSNL/sham surgery. Then, all the measurements were performed at
day 10 after pSNL/sham surgery and 60 min after treatment with HC03, A96, αLA,
GKT, PBN, ML171, gp91ds-tat peptide, or anti-CCL2 antibody. In Trpa1+/+, Trpa1
−/−, Plp1-CreERT;Trpa1fl/fl, control, and C57BL/6 mice pretreated with RTX or
treated with TRPA1, NOX1, NOX2, NOX4 AS/MM-ODN, anti-CCL2 antibody or
LCL, H2O2 content was assessed 10 days after pSNL/sham surgery. H2O2 was
determined by using the Amplex Red® assay (Invitrogen, Milan, Italy). Briefly,
sciatic nerves were rapidly removed and placed into modified Krebs/HEPES buffer
(composition in mmol l−1: 99.01 NaCl, 4.69 KCl, 2.50 CaCl2, 1.20 MgSO4, 1.03
KH2PO4, 25.0 NaHCO3, 20.0 Na-HEPES, and 5.6 glucose [pH 7.4]). Samples were
minced and incubated with Amplex red (100 µM) and HRP (1 Uml−1) (60 min, 37
°C) in modified Krebs/HEPES buffer protected from light77. Fluorescence excita-
tion and emission were at 540 and 590 nm, respectively. H2O2 production was
calculated using H2O2 standard and expressed as µmol l−1 of mg of dry tissue.
Cell culture. HEK293 cells stably transfected with the cDNA for human TRPA1
(hTRPA1-HEK293, kindly donated by A.H. Morice, University of Hull, Hull, UK)
and naive untransfected HEK293 cells (American Type Culture Collection, Man-
assas, VA, USA; ATCC® CRL-1573™), were cultured as previously described78. For
all cell lines, the cells were used when received without further authentication.
Schwann cells were isolated from sciatic nerves of C57BL/6, Trpa1+/+, Trpa1−/−,
Plp1-CreERT;Trpa1fl/fl, or control mice. Briefly, the epineurium was removed, and
nerve explants were divided into 1 mm segments and dissociated enzymatically
using collagenase (0.05%) and hyaluronidase (0.1%) in HBSS (2 h, 37 °C). Cells
were collected by centrifugation (800×rpm, 10 min, RT) and the pellet was
resuspended and cultured in DMEM containing: 10% FCS, 2 mM L-glutamine,
100 Uml−1 penicillin/100 mgml−1 streptomycin or 50 mgml−1 gentamycin. Three
days later, cytosine arabinoside (10 mM) was added to remove fibroblasts. To
enhance Schwann cell proliferation, forskolin (2 µM) was added to the culturing
medium79.
To obtain cultured peritoneal macrophages, C57BL/6 mice were i.p. injected
with thioglycolate (3%, 1 ml). After 3 days, cells were harvested from sacrificed
animals by peritoneal lavage for a total of 10 ml PBS and centrifuged (400 × g,
10 min, 4 °C). Cells were cultured in DMEM supplemented with 10% FBS. After
incubation at 37 °C for 24 h, non-adherent cells were removed by repeated
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washing80. Before each experiment, cells were tested with specific kits for cells
mycoplasma contamination based on PCR (EMK090020, N-GARDE kit,
Euroclone, Milan, Italy).
Measurement of H2O2 released from cells. H2O2 was determined by using the
Amplex Red assay (Invitrogen, Milan, Italy). hTRPA1-HEK293 or naive untrans-
fected HEK293, Schwann cells or peritoneal macrophages were plated in 96-well
clear bottom black (5 × 105 cells well−1) and maintained in 5% CO2 and 95% O2
(24 h, 37 °C). The cultured medium was replaced with Krebs-Ringer phosphate
(KRP, composition in mmol l−1: 2 CaCl2; 5.4 KCl; 0.4 MgSO4; 135 NaCl; 10 D-
glucose; 10 HEPES [pH 7.4]) added with HC03, A96 (both 30 µM) or vehicle (0.3%
DMSO) for 10 min at RT. Peritoneal macrophages were incubated with GKT
(100 nM) or gp91ds-tat (0.1–100 nM) for 20 min. hTRPA1-HEK293, naive
HEK293 or Schwann cells were stimulated with AITC (10 and 100 µM, respec-
tively), H2O2 (200 nM) or their vehicle (0.01% DMSO or KRP, respectively),
peritoneal macrophages were stimulated with phorbol myristate acetate (PMA,
20 nM) or vehicle (0.00001% DMSO diluted in KRP) added with Amplex red (50
µM) and HRP (1 Uml−1), and maintained for 30 min at RT protected from light.
Some experiments in Schwann cells were performed in Ca2+-free KRP containing
EDTA (1mM). Signal was detected 60 min (hTRPA1-HEK293/naïve-HEK293) or
40, 50, and 60 min (Schwann cells) after exposure to the stimulus. H2O2 release was
calculated using H2O2 standards and expressed as nmol l−1.
Calcium imaging. Schwann cells and macrophages were plated on glass coated
(poly-L-lysine, 8.3 µM) coverslips and intracellular calcium response was measured
as previously reported81. Schwann cells were challenged with the selective TRPA1
agonist, AITC (1 mM), and the selective TRPV1 and TRPV4 agonists, CPS (0.5
µM) and GSK1016790A (GSK, 50 nM), respectively. Results are expressed as %
increase in Ratio340/380 over baseline normalized to the maximum effect induced by
ionomycin (5 µM) added at the end of each experiment (% change in R340/380).
Macrophages were stimulated with fresh medium containing 100 ng ml−1 LPS, then
incubated at 37 °C for 6, 12, 18, 24, 36 and 48 h, before being challenged with AITC
(1 mM) and ionomycin (5 µM). Results are expressed as Ratio340/380.
Immunofluorescence and confocal microscopy. Anesthetized mice were trans-
cardially perfused with PBS, followed by 4% paraformaldehyde. The sciatic nerves
(ipsilateral to the surgery) or dorsal root ganglia (DRGs, L4-L6) were removed,
postfixed for 24 h, and paraffin embedded or cryoprotected overnight at 4 °C in
30% sucrose until cryosectioning. Cryosections (10 µm) were stained with hema-
toxylin and eosin (H&E) for histological examination or incubated with the fol-
lowing primary antibodies: F4/80 (MA516624, rat monoclonal (Cl:A3-1), 1:50,
Thermo Fisher Scientific, Rockford, USA), CD8 (ab22378, rat monoclonal
(YTS169.4), 1:200, Abcam, Cambridge, UK) and Ly6G (ab25377, rat monoclonal
(RB6-8C5), 1:200, Abcam, Cambridge, UK) (1 h, RT), diluted in fresh blocking
solution (PBS, pH 7.4, 10% normal goat serum, NGS). Formalin fixed paraffin-
embedded sections (5 µm) were incubated with the following primary antibodies:
protein gene product 9.5 (PGP9.5, ab8189, mouse monoclonal [13C4/I3C4], 1:600,
Abcam, Cambridge, UK), TRPA1 (ab58844, rabbit polyclonal, 1:400, Abcam,
Cambridge, UK), S100 (ab14849, mouse monoclonal (4B3), 1:300, Abcam, Cam-
bridge, UK), SOX10 (ab216020, mouse monoclonal (SOX10/1074), 1:300, Abcam,
Cambridge, UK), 4- HNE (ab48506, mouse monoclonal (HNEJ-2), 1:40, Abcam,
Cambridge, UK) or NOX1 (ab131088, rabbit polyclonal, 1:250, Abcam, Cambridge,
UK) (1 h, RT) diluted in antibody diluent (Roche Diagnostics, Mannheim, Ger-
many). Sections were then incubated with fluorescent secondary antibodies:
polyclonal Alexa Fluor 488, polyclonal Alexa Fluor 594, polyclonal Alexa Fluor 546,
and polyclonal Alexa Fluor 647 (1:600, Invitrogen, Milan, Italy) (2 h, RT, protected
from light). Sections were coverslipped using a water-based mounting medium
with 4′6′-diamidino-2-phenylindole (DAPI) (Abcam, Cambridge, UK). The ana-
lysis of negative controls (non-immune serum) was simultaneously performed to
exclude the presence of non-specific immunofluorescent staining, cross-immu-
nostaining, or fluorescence bleed-through. Tissues were visualized and digital
images were captured using an Olympus BX51 or confocal scan a LEICA TCS SP5.
High power 3D renderings of the images were obtained using ImageJ 3D viewer.
Direct counting of F4/80+ cells was performed in 104 μm2 boxes in the sciatic
nerve (inside the nerve trunk) in: Trpa1+/+, Trpa1−/−, Plp1-CreERT;Trpa1fl/fl, and
control mice, 10 days after pSNL/sham surgery, and in pSNL/sham C57BL/6 mice
at day 10 after surgery following treatment with RTX, CCL2-Ab, LCL and TRPA1,
NOX1, NOX2, NOX4 AS/MM-ODN and at different time points after
administration of A96, αLA, GKT, PBN, ML171, gp91ds-tat peptide or CCL2-Ab.
In some samples, direct counting of F4/80+ cells was performed in pSNL/sham
C57BL/6 mice in 104 μm2 boxes outside the sciatic nerve trunk at two different
distances (~0–200 µm and ~ 200–400 µm from the epineurium) before and after
HC03 or αLA. Direct counting of CD8+ and Ly6G+ cells was performed in 104 μm2
boxes in the sciatic nerve (inside the nerve trunk) in pSNL/sham C57BL/6 mice at
day 10 after surgery. The counting was performed by an operator blinded to drug
treatment and timing.
TRPA1 staining in DRG was evaluated as the fluorescence intensity measured
by an image processing software (ImageJ 1.32J, National Institutes of Health,
Bethesda, USA). The Pearson correlation (Rcoloc) value for TRPA1 and S100 in
the colocalization studies were calculated using the colocalization Plugin of the
ImageJ software82. Schwann cells were grown on glass coated (poly-L-lysine, 8.3
µM) coverslips and cultured for 2–3 days before being used for staining. Cells were
then fixed in ice-cold methanol/acetone (5 min at −20 °C), washed with PBS and
blocked with NGS (10%) (1 h, RT). The cells were then incubated with the primary
antibodies (TRPA1, ab58844, rabbit polyclonal, 1:400; S100, ab14849, mouse
monoclonal (4B3), 1:300, SOX10, ab216020, mouse monoclonal (SOX10/1074),
1:300, Abcam, Cambridge, UK) (1 h, RT). Cells were then incubated with
fluorescent secondary antibodies (1:600, polyclonal Alexa Fluor 488, and polyclonal
Alexa Fluor 594, Invitrogen, Milan, Italy) (2 h, RT) and mounted using water-based
mounting medium DAPI (Abcam, Cambridge, UK). Cells were visualized and
digital images were captured using an Olympus BX51.
Real-time PCR. RNA was extracted from cultured Schwann cells or peritoneal
macrophages obtained from C57BL/6 mice, and from the sciatic nerve or L4-L6
DRGs (ipsilateral to the surgery) of pSNL C57BL/6 mice after TRPA1, NOX1 and
NOX4 scrambled/AS/MM-ODN (i.t. or p.n.) To avoid the confounding con-
tribution of NOX2 mRNA from invading macrophages, for this analysis RNA was
extracted from the sciatic nerve (ipsilateral to the surgery) of sham C57BL/6 mice.
RNA was also extracted from sciatic nerve of Plp1-CreERT;Trpa1fl/fl and control.
The standard Trizol extraction method was used. RNA concentration and purity
was assessed spectrophotometrically by measuring the absorbance at 260 and
280 nm. The RNA (100 ng) was reverse-transcribed using the iScript cDNA
Synthesis kit (Bio-Rad, Hercules, USA) according to the manufacturer’s protocol.
For relative quantification of mRNA, real-time PCR was performed on Rotor Gene
Q (Qiagen, Hilden, GE). The sets of primers-probes were as follows: 18S-FW
(forward): 5′-CGCGGTTCTATTTTGTTGGT-3′, 18S-RE (reverse): 5′-AGTCGG
CATCGTTTATGGTC-3′ (NCBI Ref Seq: NR_003278.3); TRPA1-FW: 5′-CAGG
ATGCTACGGTTTTTTCATTACT-3′, TRPA1-RE: 5′-GCATGTGTCAATGTTT
GGTACTTCT-3′ (NCBI Ref Seq: NM_177781.4); S100-FW: 5′-TGGATGAAAAC
GGAGATGGGG-3′, S100-RE: 5′-ACAGACTGTGCTCAACTGGT-3′ (NCBI Ref
Seq: NM_011309); SOX10-FW: 5′-AGATCCAGTTCCGTGTCAATAA-3′,
SOX10-RE:5′GCGAGAAGAAGGCTAGGTG-3′ (NCBI Ref Seq: U70441.1);
NOX1-FW: 5′-CACTCACCAATGCCCAGGAT-3′, NOX1-RE: 5′-TGGAAGCAA
AGGGAGTGACC-3′ (NCBI Ref Seq: NM_172203.2); NOX2-FW: 5′-GAGGTTG
GTTCGGTTTTGGC-3′, NOX2-RE: 5′-CAGGAGCAGAGGTCAGTGTG-3′
(NCBI Ref Seq: NM_007807.5); NOX4-FW: 5′-TGTTGGGCCTAGGATTGTGT-
3′, NOX4-RE: 5′-TCCTGCTAGGGACCTTCTGT-3′ (NCBI Ref Seq:
NM_015760.5); F4/80-FW: 5′-CCCAGCTTATGCCACCTGCA-3′, F4/80-RE: 5′-
TCCAGGCCCTGGAACATTGG-3′ (NCBI Ref Seq: NC_000083.6); Floxed
TRPA1-FW: 5′-GGGCAGCTTATTGCCTTCAC-3′, Floxed TRPA1-RE: 5′-TTGC
GTAAGTACCAGAGTGGC-3′ (NCBI Ref Seq: NM_177781.4)
The chosen reference gene was the 18S. The SsoAdvanced™ Universal SYBR
Green Supermix (Bio-Rad, Hercules, USA) was used for amplification, and the
cycling conditions were the following: samples were heated to 95 °C for 1 min
followed by 40 cycles of 95 °C for 10 s, and 65 °C for 20 s. PCR reaction was carried
out in triplicate. Relative expression of TRPA1 mRNA was calculated using the 2−Δ
(ΔCT) comparative method, with each gene normalized against the internal
endogenous reference 18S gene for the same sample.
Protein extraction and western immunoblot assay. Cultured Schwann cells and
DRGs (L4–L6) neurons were homogenized in a lysis buffer containing (mM): 50
Tris, 150 NaCl, 2 EGTA, 100 NaF, 1 Na3VO4, 1% Nonidet P40 (pH 7.5) and
complete protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany).
Lysates were centrifuged at 14,000 × g at 4 °C for 45 min. Protein concentration in
supernatants was determined using DC protein assay (Bio-Rad, Milan, Italy).
Samples with equal amounts of proteins (20 µg) were then separated by NuPAGE
4–12% Bis–Tris gel electrophoresis (Life Technologies, Carlsbad, USA), and the
resolved proteins were transferred to a polyvinylidenedifluoride membrane (Merck
Millipore Billerica, USA). Membranes were incubated with 5% dry milk in Tris
buffer containing 0.1% Tween 20 (TBST; 20 mM Tris at pH 7.5, 150 mM NaCl) for
1 h at RT, and incubated with TRPA1 (NB110-40763, rabbit polyclonal, 1:200,
Novus Biologicals, Littleton, USA) or β-actin (mouse monoclonal primary anti-
body, 1:6000, Thermo Scientific, Rockford, USA) antibodies, at 4 °C overnight.
Membranes were then probed with goat anti-mouse or donkey anti-rabbit IgG
conjugated with horseradish peroxidase (HRPO) (Bethyl Laboratories Inc., Cam-
bridge, UK) for 1 h at RT. Finally, membranes were washed three times with TBST,
and bound antibodies were detected using chemiluminescence reagents (ECL,
Pierce, Thermo Scientific, Rockford, USA). The density of specific bands was
measured using an image processing program (ImageJ 1.32J, National Institutes of
Health, Bethesda, USA) and normalized to β-actin24. The uncropped scan of the
blot is reported in the Supplementary Fig. 7.
Live animal imaging. Macrophage localization in vivo was obtained by NIR
imaging of the fluorescent label macrophage mice by using PhotonImager (Bio-
space Laboratory, Paris, France)83. Mouse thioglycollate-elicited peritoneal mac-
rophages were harvested (up to 250 × 106 cells per ml) and incubated for 15 min at
RT with VivoTrack 680 (PerkinElmer, Inc., Waltham, USA), dissolved in sterile
PBS, washed, centrifuged (400 × g, 10 min) and diluted to a final concentration of
5 × 106 cells 40 μl−1. Retro-orbital vein injection (40 μl) of labeled macrophages was
performed in pSNL/sham C57BL/6 mice at day 9 after surgery. Twenty-four h later,
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anesthetized mice were put inside the pre-heated chamber. NIR imaging was
performed before and 1 and 3 h after HC03 (100 mg kg−1, i.p.) administration.
Images were acquired with Photo Acquisition software and processed with M3
Vision software (Biospace Laboratory, Paris, France). The NIR pixel area was
measured by ImageJ 1.32J from a region of the same size over the sciatic nerve,
identifying an area of interest (ROI) around the fluorescent signal evident in the
pSNL. That ROI perimeter was then reported to other images derived from dif-
ferent experimental settings. Data were expressed as NIR pixel area/ROI pixel area.
Statistical analysis. Statistical analysis was performed by the unpaired two-tailed
Student’s t-test for comparisons between two groups and the one-way or two-way
ANOVA followed by the post hoc Bonferroni’s test for comparisons of multiple
groups. Sample sizes for experiments were determined based on previous studies,
to ensure appropriate statistical power. P< 0.05 was considered statistically sig-
nificant (GraphPad Prism version 5.00, La Jolla, USA).
Data availability. The data that support the findings of this study are available
from the corresponding author on reasonable request.
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